Michigan Medicine, formerly the University of Michigan Health System, is the wholly owned academic medical center of the University of Michigan, in Ann Arbor.

During the past decade, University of Michigan Health System conducted 253 clinical trials. In the 10-year time frame, 253 clinical trials started and 156 clinical trials were completed, i.e. on average, 61.7% percent of trials that started reached the finish line to date. In the past 5 years, 89 clinical trials started and 95 clinical trials were completed. i.e. 106.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Michigan Health System" #1 sponsor was "University of Michigan" with 102 trials, followed by "Pfizer" with 25 trials sponsored, "Bristol-Myers Squibb" with 13 trials sponsored, "Medtronic Cardiovascular" with 12 trials sponsored and "Novartis Pharmaceuticals" with 12 trials sponsored. Other sponsors include 299 different institutions and companies that sponsored additional 190 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Michigan Health System" #1 collaborator was "University of Michigan" with 17 trials as a collaborator, "Cystic Fibrosis Foundation" with 10 trials as a collaborator, "National Institutes of Health (NIH)" with 10 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 9 trials as a collaborator and "National Cancer Institute (NCI)" with 8 trials as a collaborator. Other collaborators include 296 different institutions and companies that were collaborators in the rest 223 trials.

According to Clinical.Site data, the most researched conditions in "University of Michigan Health System" are "Cystic Fibrosis" (28 trials), "Heart Failure" (13 trials), "Prostate Cancer" (12 trials), "Breast Cancer" (11 trials) and "Crohn's Disease" (8 trials). Many other conditions were trialed in "University of Michigan Health System" in a lesser frequency.

Most popular intervention types in "University of Michigan Health System" are "Drug" (265 trials), "Device" (59 trials), "Other" (43 trials), "Procedure" (36 trials) and "Biological" (32 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (80 trials), "IVA" (9 trials), "Gemcitabine" (8 trials), "Pembrolizumab" (8 trials) and "CP-690,550" (6 trials). Other intervention names were less common.

The vast majority of trials in "University of Michigan Health System" are 422 trials for "All" genders, 24 trials for "Female" genders and 20 trials for "Male" genders.

Currently, there are NaN active trials in "University of Michigan Health System". undefined are not yet recruiting, 61 are recruiting, 49 are Active, not recruiting, and 8 are Enrolling by invitation. In total, there were 263 completed trials in University of Michigan Health System, 2 suspended trials, and 58 terminated clinical trials to date.

Out of the total trials that were conducted in University of Michigan Health System, 58 "Phase 1" clinical trials were conducted, 132 "Phase 2" clinical trials and 106 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 17 trials, and there were also 103 trials that are defined as “Not Applicable".

University of Michigan Health System has several departments that took part in Clinical trials: "University of Michigan Scleroderma Program" - 6 trials, "University of Michigan Health System Cystic Fibrosis Center" - 2 trials